#None #Securities Law #DJS Law Group #Capricor

Capricor Therapeutics Under Fire: Class Action Lawsuit Highlights Serious Allegations

In a recent development that has caught the attention of investors and market watchers alike, Capricor Therapeutics, Inc. has been named in a class action lawsuit stemming from alleged violations of securities laws. The lawsuit, initiated by the DJS Law Group, raises serious concerns regarding the company's compliance with regulatory standards and its communication with shareholders.

Background on the Company

Capricor Therapeutics, a biotechnology firm traded on NASDAQ under the symbol CAPR, focuses on developing therapies aimed at treating serious medical conditions. However, the recent allegations suggest that the company may have misled investors regarding its clinical data analysis methods, particularly concerning its product, Deramiocel.

Key Allegations

The lawsuit points to specific actions taken by Capricor that may have compromised the integrity of its market communications. According to the complaint, the company allegedly modified its statistical analysis plan for clinical trials without securing prior approval from the FDA, which is a critical regulatory step. Such alterations are said to have rendered Capricor's public statements misleading during the class period from December 17, 2025, to July 26, 2026.

The DJS Law Group has encouraged all shareholders who purchased CAPR shares during this time frame to step forward and consider their legal options. Potential participants in the lawsuit can join the case to recover alleged losses incurred as a result of these purported violations.

The Legal Road Ahead

With a deadline for participation set for September 28, 2026, investors are urged to act swiftly to protect their rights. The law group emphasizes that one does not need to be appointed as a lead plaintiff to partake in possible recovery efforts. This approach ensures that all individuals affected by these allegations can have a voice in the proceedings.

The DJS Law Group, known for its focus on helping investors navigate complex securities law issues, stresses the importance of holding corporations accountable, particularly in cases where misleading information has been disseminated to the market. The firm works with clients that include hedge funds and asset managers, providing them with legal advocacy to ensure fair treatment in the marketplace.

Conclusion

Investors in Capricor Therapeutics find themselves in a precarious situation as the company faces serious allegations of securities law violations. Transparency and ethical governance are vital in maintaining investor trust, and this lawsuit serves as a reminder of the importance of regulatory compliance in the biotech sector. Those feeling the impact of the company's alleged missteps are encouraged to reach out to the DJS Law Group for guidance and support in potentially recovering losses incurred.

For further inquiries, feel free to contact:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]